Biologics: how far can they go in Crohn’s disease?
Katie A. Dunleavy, Darrell S. Pardi
Abstract
Crohn's disease is a chronic gastrointestinal inflammatory disorder, characterized by episodes of relapsing and remitting flares. As the disease mechanism becomes better elucidated, there is a significant increase in the number of available biologic therapies. This article summarizes and synthesizes current Food and Drug Administration-approved biological therapy for Crohn's disease and examines the positioning of medical therapy as emerging biologics break onto the market.
Topics & Concepts
MedicineCrohn's diseaseDiseaseFood and drug administrationMechanism (biology)InfliximabInflammatory bowel diseaseIntensive care medicineInternal medicinePharmacologyEpistemologyPhilosophyInflammatory Bowel DiseaseMicroscopic ColitisAutoimmune and Inflammatory Disorders